Anavex Life Sciences Corporation (AVXL) is looking forward to a strong quarter

With 0.72 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.68 million shares. The 52-week range on AVXL shows that it touched its highest point at $14.44 and its lowest point at $3.25 during that stretch. It currently has a 1-year price target of $34.33. Beta for the stock currently stands at 0.82.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVXL was up-trending over the past week, with a rise of 9.61%, but this was down by -3.02% over a month. Three-month performance dropped to -3.45% while six-month performance rose 54.27%. The stock gained 74.10% in the past year, while it has lost -19.27% so far this year. A look at the trailing 12-month EPS for AVXL yields -0.55 with Next year EPS estimates of 1.32. For the next quarter, that number is -0.15. This implies an EPS growth rate of -22.44% for this year and 307.33% for next year.

Float and Shares Shorts:

At present, 84.99 million AVXL shares are outstanding with a float of 82.47 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AVXL since 6 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.54333 being high and -$0.54333 being low. For AVXL, this leads to a yearly average estimate of -$0.54333.